KRAS and neoplasm: Table 3 outlines median PFS and HRs for high and low AURKA-CN tumours by KRAS mutational status and the use of cetuximab. Interestingly, among patients with KRAS wild-type tumours, high AURKA-CN appeared to have the largest association with outcome among patients who did not receive cetuximab.